Diabetes therapy related to etiology. Indications, uses and side effects of new insulin sensitizers
Ludvik, B.
MMW Fortschritte der Medizin 142(28-29): 27-28
2000
ISSN/ISBN: 1438-3276 PMID: 10959156 Document Number: 514692
Via their central point of attack on the nuclear PPAR gamma receptors, thiazolidinediones improve insulin sensitivity and thus bring lower blood sugar and insulin levels. Depending on the group of patients investigated, they reduce the HbA1c by 0.7% to 1.5%. Rosiglitazone and pioglitazone will soon be available on the European market. In contrast to troglitazone they show no signs of any hepatotoxic effect in the studies performed to date. Common to the class of insulin sensitizers is their effect in promoting the differentiation of subcutaneous adipocytes, leading to subsequent weight increase and the development of edema.